ClinicalTrials.gg
RecruitingNCT06422143Updated Nov 17, 2026

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

A Phase 3 interventional study of Pembrolizumab and sac-TMT in Non-small Cell Lung Cancer and NSCLC, sponsored by Merck Sharp & Dohme LLC. Recruiting at 218 sites in 26 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.
Updated Nov 17, 2026Site recruiting status changed4 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
851
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing sacituzumab tirumotecan in Carcinoma, Non-Small-Cell Lung — 16 open to participants now, 26 under way, 9 of them phase 3. sacituzumab tirumotecan · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
2nd of 26
851 · median 115
Started
2024
with 5 others
Phase 3
9 of 26
3 open now
Primary completion
2029-01
later than 23 of 25 live
Registered
10th of 26
by date
Lead sponsor
6 of 26
Merck Sharp & Dohme LLC

Among the 26 studies testing sacituzumab tirumotecan in Carcinoma, Non-Small-Cell Lung, this one is the 2nd largest by planned enrollment, is one of 6 that started in 2024, is one of 9 in phase 3, reaches primary completion later than 23 of the 25 other live ones, and was the 10th registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

16 of the 26 studies testing sacituzumab tirumotecan in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About sacituzumab tirumotecan

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing sacituzumab tirumotecan in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a phase 3 study of pembrolizumab in combination with carboplatin/taxane (paclitaxel or nab-paclitaxel) followed by pembrolizumab with or without maintenance sacituzumab tirumotecan (sac-TMT; MK-2870) in first-line treatment of metastatic squamous non-small cell lung cancer. It is hypothesized that pembrolizumab with maintenance sacituzumab tirumotecan is superior to pembrolizumab without sacituzumab tirumotecan maintenance with respect to overall survival (OS).

Read the detailed description

All participants undergo an initial induction phase of four cycles, each cycle consisting of pembrolizumab every 3 weeks (q3w) + carboplatin q3w + paclitaxel q3w or nabpaclitaxel weekly. Participants are then randomly assigned to pembrolizumab maintenance vs. pembrolizumab + sac-TMT maintenance.

03

Conditions studied

  • Non-small Cell Lung Cancer
  • NSCLC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed diagnosis of squamous non-small cell lung cancer (NSCLC) [Stage IV: M1a, M1b, M1c, American Joint Committee on Cancer Staging Manual, version 8]
  • per (RECIST) 1.1 as assessed by the local site investigator/radiology
  • Has ≥3 months
  • Has Performance Status (ECOG PS) score of 0 or 1 assessed within 7 days prior to allocation
  • sample or newly obtained core, incisional, or excisional biopsy of a tumor lesion not previously irradiated has been provided
  • (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART)
  • Participants who are surface antigen (HBsAg)-positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load before allocation
  • Participants with history of virus (HCV) infection are eligible if HCV viral load is undetectable at screening
  • Participants who have adverse events (AEs) due to previous anticancer therapies must have recovered to Grade ≤1 or baseline (participants with endocrine-related AEs who are adequately treated with hormone replacement are eligible)
  • Has adequate organ function
  • For Maintenance only (prior to randomization): is without disease progression of their NSCLC, as determined by BICR using RECIST 1.1 after completion of study-specified Induction with an evaluable scan at Week 12 or most recent scan before randomization
  • For Maintenance only (prior to randomization): has ECOG PS of 0 or 1 as assessed at the Prerandomization Visit
  • For Maintenance only (prior to randomization): all AEs (with the exception of alopecia, Grade ≤2 fatigue, Grade ≤2 peripheral neuropathy, and Grade ≤2 endocrine-related AEs requiring treatment or hormone replacement) have recovered
  • For Maintenance only (prior to randomization): has not experienced a pneumonitis/interstitial lung disease (ILD) event during the study-specified induction

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements
  • History of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
  • Active inflammatory bowel disease requiring medication or previous history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, or chronic diarrhea)
  • Has uncontrolled, significant cardiovascular disease or cerebrovascular disease including Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of interval to >480 ms, and other serious cardiovascular and cerebrovascular diseases within 6 months before study intervention
  • -infected participants who have been newly diagnosed or with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
  • Received prior systemic chemotherapy or other targeted or biological antineoplastic therapy for their NSCLC. Note: Prior treatment with chemotherapy and/or radiation as a part of or adjuvant therapy or chemoradiation therapy for nonmetastatic NSCLC is allowed as long as therapy was completed at least 12 months before diagnosis of metastatic NSCLC
  • Received prior therapy with an anti-programmed cell death 1 protein (), anti-programmed cell death ligand 1 (PD-L1), or anti programmed cell death ligand 2 (PD-L2) agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, cytotoxic T lymphocyte-associated protein 4, OX-40, CD137). Note: Prior treatment with an anti-PD-1 or anti-PD-L1 agent for nonmetastatic NSCLC is allowed as long as therapy was completed at least 12 months before diagnosis of metastatic NSCLC
  • Received prior treatment with a trophoblast cell-surface antigen 2 (TROP2)-targeted antidrug conjugate (ADC)
  • Received radiation therapy to the lung that is >30 Gray within 6 months of start of study intervention
  • Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring
  • Received a live or within 30 days before the first dose of study intervention
  • Participants who have not adequately recovered from major surgery or have ongoing surgical complications
  • Received prior treatment with a topoisomerase I inhibitor-containing ADC
  • Is currently receiving a strong inducer/inhibitor of that cannot be discontinued for the duration of the study (the required before starting sac-TMT is 2 weeks)
  • Has a known additional that is progressing or has required active treatment within the past 3 years.
  • Has known central nervous system (CNS) metastases/carcinomatous meningitis
  • Severe (≥Grade 3) to study intervention and/or any of its or to another biologic therapy
  • Active disease that has required systemic treatment in the past 2 years (replacement therapy [eg, thyroxine, insulin, or physiologic corticosteroid] is allowed)
  • Has a history of (noninfectious)pneumonitis/ILD that required steroids, has current pneumonitis/ILD, or has suspected ILD or pneumonitis that cannot be ruled out by standard diagnostic assessments at Screening
  • Active infection requiring systemic therapy
  • History of allogeneic tissue/solid organ transplant
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
851 participants (estimated)

Study arms

  • Experimental
    Maintenance Arm A: Pembrolizumab + sac-TMT

    During the Induction phase, participants receive pembrolizumab 200 mg q3w for 4 cycles, carboplatin area under the curve (AUC) 6 (mg/mL/min) q3w for 4 cycles, and paclitaxel 200 mg/m2 q3w for 4 cycles or nab-paclitaxel 100 mg/m2 weekly for 4 cycles. Note: per investigator discretion, carboplatin AUC 5 mg/mL/min q3w or paclitaxel 175mg/m2 q3w may be administered. During the Maintenance phase, participants receive sac-TMT 4 mg/kg infusion every 2 weeks (q2w) until discontinuation criteria is met for sac-TMT; and pembrolizumab 400 mg every 6 weeks (q6w) for 96 weeks.

    Biological: Pembrolizumab · Biological: sac-TMT · Drug: Carboplatin · Drug: Paclitaxel · Drug: Nab-paclitaxel

  • Active comparator
    Maintenance Arm B: Pembrolizumab Monotherapy

    During the Induction phase, participants receive pembrolizumab 200 mg q3w for 4 cycles, carboplatin AUC 6 (mg/mL/min) q3w for 4 cycles, and paclitaxel 200 mg/m2 q3w for 4 cycles or nab-paclitaxel 100 mg/m2 weekly for 4 cycles. During the Maintenance phase, participants receive pembrolizumab 400 mg q6w for 96 weeks.

    Biological: Pembrolizumab · Drug: Carboplatin · Drug: Paclitaxel · Drug: Nab-paclitaxel

Interventions

  • BiologicalPembrolizumab

    Intravenous (IV) infusion

    Also known as: KEYTRUDA®, MK-3475, SCH 900475

  • Biologicalsac-TMT

    IV infusion

    Also known as: MK-2870, Sacituzumab tirumotecan

  • Participants receive AUC 6 or AUC 5 mg/mL/min IV infusion on Day 1 of each 21-day cycle for 4 cycles as background therapy during the study.

  • Participants receive 200 mg/m\^2 or 175 mg/m\^2 IV infusion on Day 1 of each 21-day cycle for 4 cycles as background therapy during the study.

  • Participants receive 100 mg/m\^2 IV infusion on Days 1, 8 and 15 of each 21-day cycle for 4 cycles as background therapy during the study.

06

What researchers measure

Primary outcomes

  1. Overall survival (OS)

    OS is the time from randomization to death due to any cause.

    Time frame: Up to ~50 months

Secondary outcomes

  1. Progression-Free Survival (PFS)

    PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1).

    Time frame: Up to ~79 months

  2. Number of Participants With ≥1 Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to ~79 months

  3. Number of Participants Discontinuing from Study Therapy Due to AE(s)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to ~79 months

  4. Change in Score from Baseline to a Predefined Timepoint in Participant-Reported Global health status/Quality of Life (QoL) Score (EORTC QLQ-C30 Items 29 and 30)

    European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) is a 30-item scale to assess the overall quality of life in cancer patients. The global health status and QoL scores are based on participant responses to items 29 ("How would you rate your overall health during past week?") and 30 ("How would you rate your overall quality of life during the week?") that are scored on a 7-point scale (1 = "Very poor" to 7 = "Excellent"). Higher scores indicate better overall health status.

    Time frame: Baseline and up to ~79 months

  5. Change in Score from Baseline to a Predefined Timepoint in Participant-Reported Dyspnea (EORTC QLQ-C30 Item 8)

    EORTC QLQ-C30 is a 30-item scale to assess the overall quality of life of cancer patients. The dyspnea score is based on participant responses to item 8 ("Were you short of breath?") that is scored on a 4-point scale (1 = 'Not at All' to 4 = 'Very Much'). Higher scores indicate worse dyspnea symptoms.

    Time frame: Baseline and up to ~79 months

  6. Change in Score from Baseline to a Predefined Timepoint in Participant-Reported Cough (EORTC QLQ-LC13 Item 31)

    EORTC QLQ-C13 is a 13-item addendum to EORTC QLQ-C30 to assess the overall quality of life of lung cancer patients. The cough score is based on participant responses to item 31 ("How much did you cough?") that is scored on a 4-point scale (1 = 'Not at All' to 4 = 'Very Much'). Higher scores indicate worse cough.

    Time frame: Baseline and up to ~79 months

  7. Change in Score from Baseline to a Predefined Timepoint in Participant-Reported Chest Pain (EORTC QLQ-LC13 Item 40)

    EORTC QLQ-C13 is a 13-item addendum to EORTC QLQ-C30 to assess the overall quality of life of lung cancer patients. The chest pain score is based on participant responses to item 40 e (1 = "Not at All" to 4 = "Very Much").

    Time frame: Baseline and up to ~79 months

  8. Time to First Deterioration (TTD) in Global Health Status/QoL Scores (EORTC QLQ-C30 Items 29 and 30)

    EORTC QLQ-C30 is a 30-item scale to assess the overall quality of life in cancer patients. TTD in global health status and QoL scores are based on participant responses to items 29 ("How would you rate your overall health during past week?") and 30 ("How would you rate your overall quality of life during the week?") that are scored on a 7-point scale (1 = "Very poor" to 7 = "Excellent"). Higher scores indicate better overall health status.

    Time frame: Up to ~79 months

  9. TTD in Dyspnea Score (EORTC QLQ-C30 Item 8)

    EORTC QLQ-C30 is a 30-item scale to assess the overall quality of life of cancer patients. TTD in dyspnea score is based on participant responses to item 8 ("Were you short of breath?") that is scored on a 4-point scale (1 = 'Not at All' to 4 = 'Very Much'). Higher scores indicate worse dyspnea symptoms.

    Time frame: Up to ~79 months

  10. TTD in Cough Score (EORTC QLQ-LC13 Item 31)

    EORTC QLQ-C13 is a 13-item addendum to EORTC QLQ-C30 to assess the overall quality of life of lung cancer patients. TTD in cough score is based on participant responses to item 31 ("How much did you cough?") that is scored on a 4-point scale (1 = 'Not at All' to 4 = 'Very Much'). Higher scores indicate worse cough.

    Time frame: Up to ~79 months

  11. TTD in Chest Pain Score (EORTC QLQ-LC13 Item 40)

    EORTC QLQ-C13 is a 13-item addendum to EORTC QLQ-C30 to assess the overall quality of life of lung cancer patients. TTD in chest pain score is based on participant responses to item 40 ("Have you had pain in your chest?") that is scored on a 4-point scale (1 = 'Not at All' to 4 = 'Very Much'). Higher scores indicate worse chest pain.

    Time frame: Up to ~79 months

07

Study locations

173 of 218 sites recruiting
  • CARTI Cancer Center ( Site 0006)
    Little Rock, Arkansas 72205, United States
    Recruiting
    • Study Coordinator · Contact501-906-3000
  • Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center ( Site 0122)
    Burbank, California 91505, United States
    Recruiting
    • Study Coordinator · Contact818-748-4723
  • Sharp Memorial Hospital ( Site 9544)
    San Diego, California 92123, United States
    Recruiting
    • Study Coordinator · Contact858-939-7201
  • PHI Health Whittier ( Site 9502)
    Whittier, California 90602, United States
    Recruiting
    • Study Coordinator · Contact562-698-0811
  • Intermountain Health Cancer Center Lutheran Hospital ( Site 0119)
    Golden, Colorado 80401, United States
    Recruiting
    • Study Coordinator · Contact303-403-6381
  • Intermountain Health St. Mary's Regional Hospital ( Site 0116)
    Grand Junction, Colorado 81501, United States
    Recruiting
    • Study Coordinator · Contact970-298-6576
  • Washington Hospital Center ( Site 0037)
    Washington D.C., District of Columbia 20010, United States
    Recruiting
    • Study Coordinator · Contact202-877-8839
  • Mid Florida Hematology and Oncology Center ( Site 0109)
    Orange City, Florida 32763, United States
    Completed

    Not enrolling at this site — choose another above.

  • Centricity Research Columbus Cancer Center ( Site 0111)
    Columbus, Georgia 31904, United States
    Completed

    Not enrolling at this site — choose another above.

  • Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0001)
    Marietta, Georgia 30060, United States
    Completed

    Not enrolling at this site — choose another above.

  • Southeastern Regional Medical Center ( Site 0004)
    Newnan, Georgia 30265, United States
    Completed

    Not enrolling at this site — choose another above.

  • University of Chicago Medical Center ( Site 0145)
    Chicago, Illinois 60637, United States
    Recruiting
    • Study Coordinator · Contact773-352-1745
  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor ( Site 9552)
    Ypsilanti, Michigan 48197, United States
    Recruiting
    • Study Coordinator · Contact734-712-4950
  • Allina Health Cancer Institute - Abbott Northwestern Hospital ( Site 0146)
    Minneapolis, Minnesota 55407, United States
    Recruiting
    • Study Coordinator · Contact888-425-5462
  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0035)
    Hackensack, New Jersey 07601, United States
    Recruiting
    • Study Coordinator · Contact551-996-5900
  • Capital Health Medical Center - Hopewell ( Site 0034)
    Pennington, New Jersey 08534, United States
    Recruiting
    • Study Coordinator · Contact609-303-4733
  • New Mexico Oncology Hematology Consultants Ltd. ( Site 0123)
    Albuquerque, New Mexico 87109, United States
    Completed

    Not enrolling at this site — choose another above.

  • University of New Mexico Comprehensive Cancer Center ( Site 0135)
    Albuquerque, New Mexico 87131, United States
    Recruiting
    • Study Coordinator · Contact505-272-4946
  • St Luke's University Health Network ( Site 0017)
    Bethlehem, Pennsylvania 18015, United States
    Recruiting
    • Study Coordinator · Contact484-658-1792
  • Thomas Jefferson University - Clinical Research Institute ( Site 0147)
    Philadelphia, Pennsylvania 19107, United States
    Recruiting
    • Study Coordinator · Contact215-955-8874
  • Memorial Hermann Cancer Center ( Site 0015)
    Houston, Texas 77030, United States
    Recruiting
    • Study Coordinator · Contact281-540-7905
  • Oncology Consultants P.A. ( Site 0124)
    Houston, Texas 77030, United States
    Recruiting
    • Study Coordinator · Contact713-600-0913
  • Mays Cancer Center ( Site 0132)
    San Antonio, Texas 78229, United States
    Completed

    Not enrolling at this site — choose another above.

  • Instituto Alexander Fleming ( Site 0203)
    Ciudad Autónoma de Buenos Aires, Buenos Aires C1426ANZ, Argentina
    Recruiting
    • Study Coordinator · Contact3221 8900 int 8123
  • Instituto de Investigaciones Clínicas Mar del Plata ( Site 0200)
    Mar del Plata, Buenos Aires B7600FZO, Argentina
    Recruiting
    • Study Coordinator · Contact0223 496-3224
  • Instituto Médico Río Cuarto ( Site 0204)
    Río Cuarto, Córdoba Province X5800AEV, Argentina
    Recruiting
    • Study Coordinator · Contact+543584679361
  • Fundacion Intecnus ( Site 0205)
    Bariloche, Río Negro Province R8402APU, Argentina
    Recruiting
    • Study Coordinator · Contact0294 474-6050
  • Sanatorio Parque ( Site 0201)
    Rosario, Santa Fe Province S2000DSV, Argentina
    Recruiting
    • Study Coordinator · Contact0341 420-0222
  • Hospital Aleman-Oncology ( Site 0202)
    Buenos Aires, C1118AAT, Argentina
    Recruiting
    • Study Coordinator · Contact+54 11 4827-7000
  • Ordensklinikum Linz GmbH Elisabethinen-Department of Pneumology ( Site 0720)
    Linz, Upper Austria 4020, Austria
    Recruiting
    • Study Coordinator · Contact+4373276760
  • Klinik Hietzing ( Site 0740)
    Vienna, 1130, Austria
    Recruiting
    • Study Coordinator · Contact+43 1 80110 2471
  • Standort Penzing der Klinik Ottakring-Abteilung für Atemwegs-und Lungenkrankheiten ( Site 0730)
    Vienna, 1140, Austria
    Recruiting
    • Study Coordinator · Contact004319106042002
  • Klinik Floridsdorf-Abteilung für Innere Medizin und Pneumologie ( Site 0710)
    Vienna, 1210, Austria
    Recruiting
    • Study Coordinator · Contact00431277005634
  • Hospital do Cancer de Pernambuco ( Site 0312)
    Recife, Pernambuco 50040-000, Brazil
    Recruiting
    • Study Coordinator · Contact: +55 81 99631 6566
  • Vencer Centro de Pesquisa Clínica ( Site 0309)
    Teresina, Piauí 64049-200, Brazil
    Recruiting
    • Study Coordinator · Contact+55 86 99900-7799
  • Irmandade da Santa Casa de Misericórdia de Porto Alegre ( Site 0311)
    Porto Alegre, Rio Grande do Sul 90020-090, Brazil
    Recruiting
    • Study Coordinator · Contact+555132148143
  • Hospital Nossa Senhora da Conceição ( Site 0300)
    Porto Alegre, Rio Grande do Sul 91350-200, Brazil
    Recruiting
    • Study Coordinator · Contact555133572092
  • Instituto de Oncologia Saint Gallen ( Site 0304)
    Santa Cruz do Sul, Rio Grande do Sul 96830-180, Brazil
    Recruiting
    • Study Coordinator · Contact5551991898942
  • Hospital de Base de São José do Rio Preto ( Site 0310)
    São José do Rio Preto, São Paulo 15090-000, Brazil
    Recruiting
    • Study Coordinator · Contact(17) 3201-5054
  • ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 0302)
    São Paulo, 01246-000, Brazil
    Recruiting
    • Study Coordinator · Contact+ 55 11 3893-2649
  • Hospital Paulistano ( Site 0307)
    São Paulo, 01321-001, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 0100)
    Kingston, Ontario K7L 2V7, Canada
    Recruiting
    • Study Coordinator · Contact613-549-6666
  • Waterloo Regional Health Network (WRHN) ( Site 0153)
    Kitchener, Ontario N2G 1G3, Canada
    Recruiting
    • Study Coordinator · Contact519749430
  • St. Marys Hospital Center ( Site 0105)
    Montreal, Quebec H3T 1M5, Canada
    Recruiting
    • Study Coordinator · Contact514-345-3511
  • McGill University Health Centre ( Site 0103)
    Montreal, Quebec H4A 3J1, Canada
    Recruiting
    • Study Coordinator · Contact514 934-1934
  • Centre integre universitaire de sante et de services sociaux de la Mauricie-et-du-centre-du-quebec ( Site 0106)
    Trois-Rivières, Quebec G8Z 3R9, Canada
    Recruiting
    • Study Coordinator · Contact819-697-3333
  • Centro de Investigación del Maule ( Site 0419)
    Talca, Maule Region 3481349, Chile
    Completed

    Not enrolling at this site — choose another above.

  • Fundación Arturo López Pérez ( Site 0409)
    Santiago, Region M. de Santiago 7500921, Chile
    Recruiting
    • Study Coordinator · Contact+56224457254
  • Pontificia Universidad Catolica de Chile-Hemato-Oncology ( Site 0402)
    Santiago, Region M. de Santiago 8330024, Chile
    Recruiting
    • Study Coordinator · Contact+56223543334
  • Bradfordhill-Clinical Area ( Site 0407)
    Santiago, Region M. de Santiago 8420383, Chile
    Recruiting
    • Study Coordinator · Contact56229490970
  • ONCOCENTRO APYS-ACEREY ( Site 0400)
    Viña del Mar, Valparaiso 2520598, Chile
    Recruiting
    • Study Coordinator · Contact56323320850
  • Bradford Hill Norte ( Site 0420)
    Antofagasta, 1240000, Chile
    Recruiting
    • Study Coordinator · Contact56442023631
  • Beijing Cancer Hospital ( Site 2411)
    Beijing, Beijing Municipality 100142, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Beijing Cancer hospital-intrathoratic deparmtment II ( Site 2410)
    Beijing, Beijing Municipality 100142, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Peking Union Medical College Hospital ( Site 2412)
    Beijing, Beijing Municipality 100730, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Army Medical Center of People's Liberation Army-respiratory ( Site 2426)
    Chongqing, Chongqing Municipality 400042, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Fujian Provincial Cancer Hospital ( Site 2419)
    Fuzhou, Fujian 350014, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • The First Affiliated hospital of Xiamen University-oncology ( Site 2420)
    Xiamen, Fujian 361003, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • The First Affiliated Hospital of Guangzhou Medical University ( Site 2417)
    Guangzhou, Guangdong 510160, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Southern Medical University Nanfang Hospital-Depatrment of Respiratory and Critical Care Medicine ( Site 2416)
    Guangzhou, Guangdong 510515, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Harbin Medical University Cancer Hospital-oncology of department ( Site 2415)
    Harbin, Heilongjiang 150000, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Henan Cancer Hospital-Pneumology department ( Site 2423)
    Zhengzhou, Henan 450008, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Tongji Hospital Tongji Medical,Science & Technology ( Site 2424)
    Wuhan, Hubei 430000, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • The Second Xiangya Hospital of Central South University-Oncology ( Site 2418)
    Changsha, Hunan 410011, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • First Huai'an Hospital Affiliated to Nanjing Medical University ( Site 2402)
    Huai'an, Jiangsu 223300, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Northern Jiangsu People's Hospital-General Surgery Department ( Site 2403)
    Yangzhou, Jiangsu 225001, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • The First affiliated hospital of Nanchang University (Xianghu campus) ( Site 2404)
    Nanchang, Jiangxi 330006, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • The Second Affiliated Hospital of Nanchang University-Oncology Department ( Site 2405)
    Nanchang, Jiangxi 330006, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Jilin Province Tumor Hospital-GCP office ( Site 2413)
    Changchun, Jilin 130000, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • The First Hospital of Jilin University-Oncology ( Site 2414)
    Changchun, Jilin 130021, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Shanghai East Hospital ( Site 2428)
    Shanghai, Shanghai Municipality 200120, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Shanghai Pulmonary Hospital ( Site 2427)
    Shanghai, Shanghai Municipality 200433, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • West China Hospital, Sichuan University ( Site 2422)
    Chengdu, Sichuan 610041, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Sichuan Cancer hospital. ( Site 2421)
    Chengdu, Sichuan 610042, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • The Affiliated Cancer Hospital of Xinjiang Medical University ( Site 2425)
    Ürümqi, Xinjiang 830000, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • The first Affiliated Hospital, Zhejiang University School of Medicine-Respiratory Department ( Site 2406)
    Hangzhou, Zhejiang 310000, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Sir Run Run Shaw Hospital of Zhejiang University School of Medicine-Medical Oncology ( Site 2407)
    Hangzhou, Zhejiang 310016, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Zhejiang Cancer Hospital-Breast Oncology ( Site 2408)
    Hangzhou, Zhejiang 310022, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Taizhou Hospital of Zhejiang Province ( Site 2430)
    Taizhou, Zhejiang 317000, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • The First Affiliated Hospital of Wenzhou Medical University-Respiratory department ( Site 2409)
    Wenzhou, Zhejiang 325015, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Centro Cancerológico del Caribe (CECAC) ( Site 0509)
    Barranquilla, Atlántico 080002, Colombia
    Recruiting
    • Study Coordinator · Contact+573132121774
  • FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 0500)
    Bogotá, Bogota D.C. 110131, Colombia
    Recruiting
    • Study Coordinator · Contact+573219198898
  • Sociedad De Oncología y Hematología Del Cesar SAS-Oncology ( Site 0501)
    Valledupar, Cesar Department 200001, Colombia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Oncologos del Occidente ( Site 0504)
    Pereira, Risaralda Department 660001, Colombia
    Recruiting
    • Study Coordinator · Contact+57 3187715522
  • Fundación Valle del Lili-Oncology CIC ( Site 0505)
    Cali, Valle del Cauca Department 760032, Colombia
    Recruiting
    • Study Coordinator · Contact+ 57 3126160090
  • Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 0800)
    Brno, Brno-mesto 656 53, Czechia
    Recruiting
    • Study Coordinator · Contact+420532233843
  • Nemocnice AGEL Ostrava - Vitkovice a.s.-Plicni oddeleni ( Site 0803)
    Ostrava-Vitkovice, Ostrava Mesto 703 00, Czechia
    Recruiting
    • Study Coordinator · Contact+420595633400
  • Multiscan-Onkologicke a radiologicke centrum Multiscan Pardubice ( Site 0804)
    Pardubice, Pardubice Region 532 03, Czechia
    Recruiting
    • Study Coordinator · Contact+420466016436
  • Fakultni nemocnice Olomouc-Klinika plicnich nemoci a tuberkulozy ( Site 0802)
    Olomouc, 779 00, Czechia
    Recruiting
    • Study Coordinator · Contact+420588443666
  • Clinique Clairval ( Site 0904)
    Marseille, Bouches-du-Rhone 13009, France
    Recruiting
    • Study Coordinator · Contact+33496196230
  • Hôpital Robert Schuman ( Site 0907)
    Vantoux, Lorraine 57070, France
    Recruiting
    • Study Coordinator · Contact+33387536012
  • Institut de Cancérologie de l'Ouest ( Site 0908)
    Angers, Maine-et-Loire 49055, France
    Recruiting
    • Study Coordinator · Contact0244853754
  • Sainte Catherine Institut du Cancer Avignon Provence ( Site 0902)
    Avignon, Vaucluse 84000, France
    Recruiting
    • Study Coordinator · Contact+33490276397
  • CHD Vendee ( Site 0901)
    La Roche-sur-Yon, Vendee 85000, France
    Recruiting
    • Study Coordinator · Contact+33251446572
  • Hôpital Saint-Louis ( Site 0906)
    Paris, 75475, France
    Completed

    Not enrolling at this site — choose another above.

  • GEFOS Gesellschaft f. onkologische Studien ( Site 1005)
    Dortmund, North Rhine-Westphalia 44309, Germany
    Recruiting
    • Study Coordinator · Contact+492312061692
  • Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung ( Site 1001)
    Essen, North Rhine-Westphalia 45136, Germany
    Recruiting
    • Study Coordinator · Contact+4920117424003
  • Universitätsklinikum Schleswig-Holstein-Pneumologie ( Site 1000)
    Lübeck, Schleswig-Holstein 23538, Germany
    Recruiting
    • Study Coordinator · Contact+49 451 500 45002
  • SRH Wald-Klinikum Gera-Zentrum für klinische Studien ( Site 1006)
    Gera, Thuringia 07548, Germany
    Recruiting
    • Study Coordinator · Contact+493658287758
  • Charité Campus Virchow-Klinikum-Department of Infectious Diseases and Pulmonary Medicine ( Site 1003)
    Berlin, 13353, Germany
    Recruiting
    • Study Coordinator · Contact+4930450665005

Showing the first 100 of 218 sites across 26 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

5 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Jan 2029, 55 months after the start.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's planned 55 months is above that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2024
First posted
May 20, 2024
StartActual
Jun 10, 2024
Primary completionEst.
Jan 12, 2029
CompletionEst.
Aug 15, 2031
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added, 2 sites removed. Hospital Paulistano ( Site 0307) is now Active, not recruiting
Show 4 added (1 Chile, 1 Thailand, 1 Brazil, 1 United States)
  • Fundación Arturo López Pérez ( Site 0409) · Santiago, Chile
  • Bangkok Metropolitan Administration Medical College and Vajira Hospital ( Site 2300) · Bangkok, Thailand
  • ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 0302) · São Paulo, Brazil
  • PHI Health Whittier ( Site 9502) · Whittier, United States
Show 2 removed
  • FALP ( Site 0409) · Santiago, Chile
  • Bangkok Metropolitan Administration Medical College and Vajira Hospital ( Site 2300) · Dusit, Thailand
across 4 updates, Oct 6, 2026 – Nov 17, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Hospital Paulistano ( Site 0307) · São Paulo, BrazilContact removed •••1083
Oct 29, 2026
Show all 5 updates
  1. Nov 17, 2026
    1 site added
    Show site
    • PHI Health Whittier ( Site 9502) · Whittier, United States
    + 1 other change: verification date
  2. Oct 29, 2026
    Hospital Paulistano ( Site 0307) is now Active, not recruiting
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Hospital Paulistano ( Site 0307) · São Paulo, BrazilContact removed •••1083
  3. Oct 27, 2026
    Minor edits only
    + 1 other change: site details
  4. Oct 15, 2026
    1 site added
    Show site
    • ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 0302) · São Paulo, Brazil
  5. Oct 6, 2026
    2 sites added, 2 sites removed
    Show 2 added (1 Chile, 1 Thailand)
    • Fundación Arturo López Pérez ( Site 0409) · Santiago, Chile
    • Bangkok Metropolitan Administration Medical College and Vajira Hospital ( Site 2300) · Bangkok, Thailand
    Show 2 removed
    • FALP ( Site 0409) · Santiago, Chile
    • Bangkok Metropolitan Administration Medical College and Vajira Hospital ( Site 2300) · Dusit, Thailand
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06422143
Responsible party
Sponsor
First posted
May 20, 2024
Start date
Jun 10, 2024
Primary completion
Jan 12, 2029 (estimated)
Completion
Aug 15, 2031 (estimated)
Last update
Nov 17, 2026

Study contacts

Toll Free Number
Contact
Trialsites@msd.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sacituzumab tirumotecan

Start the discussion